Expertise in
26
conditions

Dr. Vishala Chindalore

Rheumatology
Anniston Medical Clinic PC
1010 Christine Ave, 
Anniston, AL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
26
conditions
Anniston Medical Clinic PC
1010 Christine Ave, 
Anniston, AL 

Overview

Vishala Chindalore is a Rheumatologist in Anniston, Alabama. Dr. Chindalore is highly rated in 26 conditions, according to our data. Her top areas of expertise are Rheumatoid Arthritis (RA), Fibromyalgia, Undifferentiated Connective Tissue Disease (UCTD), and Juvenile Primary Osteoporosis.

Her clinical research consists of co-authoring 10 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Rheumatology

Licenses

Internal Medicine in AL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

ANNISTON MEDICAL CLINIC PC
1010 Christine Ave, Anniston, AL 36207

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Multipart Exploratory Study to Evaluate Splenic Nerve Stimulation in Patients With Rheumatoid Arthritis
Multipart Exploratory Study to Evaluate Splenic Nerve Stimulation in Patients With Rheumatoid Arthritis
Enrollment Status: Recruiting
Publish Date: May 22, 2024
Intervention Type: Drug, Device
Study Phase: Not Applicable
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of VIB1116 in Conventional Dendritic Cell (cDC) and Plasmacytoid Dendritic Cell (pDC)-Mediated Rheumatic Diseases
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of VIB1116 in Conventional Dendritic Cell (cDC) and Plasmacytoid Dendritic Cell (pDC)-Mediated Rheumatic Diseases
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Drug
Study Drug: TAK-079
Study Phase: Phase 1
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus Erythematosus
A Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: March 04, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

10 Total Publications

A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
Journal: Arthritis research & therapy
Published: December 21, 2023
Similar Doctors
Kenneth Saag
Expertise in
22
conditions
Dr. Kenneth Saag
Rheumatology
Expertise in
22
conditions
Dr. Kenneth Saag
Rheumatology

University Of Alabama Health Services Foundation PC

2000 6th Ave S, 
Birmingham, AL 
 (57.1 miles away)
205-996-7438
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kenneth Saag is a Rheumatologist in Birmingham, Alabama. Dr. Saag is highly rated in 22 conditions, according to our data. His top areas of expertise are Gout, Osteoporosis, Postmenopausal Osteoporosis, and Arthritis.

Expertise in
24
conditions
Dr. Greg E. Eudy
Rheumatology
Expertise in
24
conditions
Dr. Greg E. Eudy
Rheumatology

Greg E Eudy MD PC

513 Brookwood Blvd, Suite 500, 
Birmingham, AL 
 (56.4 miles away)
205-263-0093
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Greg Eudy is a Rheumatologist in Birmingham, Alabama. Dr. Eudy is highly rated in 24 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Osteoporosis, Postmenopausal Osteoporosis, and Ankylosing Spondylitis. Dr. Eudy is currently accepting new patients.

Expertise in
21
conditions
Dr. Jeffrey Peller
Rheumatology
Expertise in
21
conditions
Dr. Jeffrey Peller
Rheumatology

Floyd Outpatient Rehabilittion Ctr

1825 Martha Berry Blvd NW, 
Rome, GA 
 (56.4 miles away)
706-295-5331
Languages Spoken:
English
See accepted insurances

Jeffrey Peller is a Rheumatologist in Rome, Georgia. Dr. Peller is highly rated in 21 conditions, according to our data. His top areas of expertise are Postmenopausal Osteoporosis, Osteoporosis, Osteopenia, and Melorheostosis with Osteopoikilosis.

Frequently Asked Questions about Dr. Vishala Chindalore

How do I make an appointment with Dr. Vishala Chindalore?

You can book an appointment with Dr. Vishala Chindalore by calling their office at 256-236-5631. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vishala Chindalore a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vishala Chindalore is classified as an Distinguished expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vishala Chindalore specialize in?

While Dr. Vishala Chindalore is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Fibromyalgia, and Undifferentiated Connective Tissue Disease (UCTD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Vishala Chindalore participate in research or clinical trials?

Yes. Dr. Vishala Chindalore has published 10 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Dr. Vishala Chindalore's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vishala Chindalore accept my insurance?

Dr. Vishala Chindalore accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 256-236-5631 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chindalore's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 14 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile